Condition: Non Small Cell Lung Cancer Stage · Sponsor: University of Kansas Medical Center
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
This description comes directly from the study's public registry record.
KUCC Navigation · 913-588-3671 · kucc_navigation@kumc.edu
Always discuss trial participation with your own doctor first.
| The University of Kansas Cancer Center, Westwood Campus | Kansas City, Kansas, United States | Recruiting |
| The University of Kansas Cancer Center, Overland Park Clinic | Overland Park, Kansas, United States | Recruiting |
| KUCC MCA- TUKHS, Saint Francis Hospital | Topeka, Kansas, United States | Not Yet Recruiting |
| The University of Kansas Cancer Center, North Clinic | Kansas City, Missouri, United States | Recruiting |
| The University of Kansas Cancer Center, Lee's Summit Clinic | Lee's Summit, Missouri, United States | Recruiting |
| University of Kansas Cancer Center, North Kansas City Hospital | North Kansas City, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04992780